457 results on '"Isola, Luis"'
Search Results
52. Effectiveness of Partner Social Support Predicts Enduring Psychological Distress After Hematopoietic Stem Cell Transplantation
53. Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m 2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m 2
54. Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma
55. A case report of secondary autograft failure due to Gaucher disease
56. A case report of concomitant paroxysmal nocturnal hemoglobinuria and sickle cell disease
57. Partial HLA matching and RH incompatibility resulting in graft versus host reaction and Evans syndrome after liver transplantation
58. Syngeneic stem cell transplant for spent-phase polycythaemia vera: eradication of myelofibrosis and restoration of normal haematopoiesis
59. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation
60. Cost implications of potentially avoidable hospitalizations among Oncology Care Model patients with prostate cancer.
61. Improving the chemotherapy consent: From paper to tablet.
62. Allogeneic Stem Cell Transplantation Overview
63. Identifying Potentially Avoidable Hospitalizations in Medicare Patients With Prostate Cancer: A Retrospective Analysis
64. Interpreting Oncology Care Model Data to Drive Value-Based Care: A Prostate Cancer Analysis
65. Revisiting the History of Haploidentical Transplantation
66. Influence of Pomalidomide and Lenalidomide on Total Cost of Care for Medicare Beneficiaries with Multiple Myeloma Under the Oncology Care Model (OCM)
67. A case of syngeneic graft-versus-host disease
68. Long-term follow-up after allogeneic granulocyte colony-stimulating factor--primed bone marrow transplantation
69. Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2.
70. A case of syngeneic graft-versus-host disease.
71. The Complexity of Reporting Hospital Acquired Infections (HAI)/Catheter Related Blood Stream Infections (CLABSI) in BMT Patients
72. Influence of ASCT for Multiple Myeloma (MM) on Total Cost of Care Under the CMS Oncology Care Model (OCM)
73. Minimizing prostate cancer admissions via enhanced outpatient care: A model for savings.
74. First Description of Ruxolitinib in JAK2+ ALL: Institutional Experience with Noted Response
75. Severe post-treatment leukopenia associated with the development of encephalopathy following ifosfamide infusion
76. 684 - The Complexity of Reporting Hospital Acquired Infections (HAI)/Catheter Related Blood Stream Infections (CLABSI) in BMT Patients
77. 376 - Influence of ASCT for Multiple Myeloma (MM) on Total Cost of Care Under the CMS Oncology Care Model (OCM)
78. Economic Survivorship Stress is Associated with Poor Health-Related Quality of Life among Distressed Survivors of Hematopoietic Stem Cell Transplantation
79. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
80. Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia
81. Donor Cell Cardiac Myeloid Sarcoma Following Umbilical Cord Transplantation
82. Secondary Graft Failure in Allogeneic Stem Cell Transplantation for Myelofibrosis - a Single Institution Experience
83. Bendamustine-Brentuximab: Bridging to Transplant
84. Ex Vivo Pharmacologic Modulation in a Nutrient-Rich Medium to Accelerate Engraftment of Human Umbilical Cord Blood
85. Donor Characteristics Affecting Graft Failure, Graft-versus-Host Disease, and Survival after Unrelated Donor Transplantation with Reduced-Intensity Conditioning for Hematologic Malignancies
86. 264 - First Description of Ruxolitinib in JAK2+ ALL: Institutional Experience with Noted Response
87. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
88. Adverse drug reaction: pomalidomide-induced liver injury
89. Palifermin Use in Lymphoma Patients Undergoing Autologous BEAM Transplants
90. Prospective Study Of Mobilization Kinetics Up To 18 Hours After Late Afternoon Dosing Of Plerixafor
91. Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor
92. Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors
93. Prospective cohort study of the circadian rhythm pattern in allogeneic sibling donors undergoing standard granulocyte colony-stimulating factor mobilization
94. Oral Glutamine and Probiotics on Enteral Morbidity Following Autologous Stem Cell Transplantation for Plasma Cell Dyscrasias
95. Pretransplant Psychiatric Evaluations - A Survey of NMDP Programs
96. Insurance Stressors in Hematopoietic Stem Cell Transplantation Questionnaire
97. Employment Stressors Measure
98. Financial Stressors Measure
99. Subjective reports of cognitive changes among hematopoietic stem cell transplant survivors
100. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.